Need for fixed combination therapy in type-2 diabetes: Findings from the SMART study

Abstract

Get full access to this article

View all access options for this article.

References

Yang

Liu

et al.

Prevalence of cardiovascular disease risk factor in the Chinese population: The 2007–2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 2012; 33: 213–220.

Wilson

Kannel

Silbershatz

et al.

Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104–1109.

Yusuf

Hawken

Ounpuu

et al.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet 2004; 364: 937–952.

Stamler

Vaccaro

Neaton

et al.

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444.

Gupta

Nasothimiou

Chang

et al.

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens 2011; 29: 2004–2013.

Authors/Task Force Members Piepoli

Hoes

et al.

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23: NP1–NP96.

Corrao

Parodi

Nicotra

et al.

Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–618.

Fung

Huang

Brand

et al.

Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. Clin Ther 2007; 29: 972–984.

Bahiru

de Cates

Farr

et al.

Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 3: CD009868–CD009868.

10.

Janssen

Visseren

de Boer

et al.

The combined use of polypill components in patients with type 2 diabetes mellitus. Eur J Prev Cardiol 2018; 25: 1523–1531.

11.

Becerra

Gracia

Desai

et al.

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open 2015; 5: e007111–e007111.

12.

Singh

Crossan

Laba

et al.

Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018; 262: 71–78.

13.

European Society of Hypertension. First look at the new 2018 European Guidelines for the treatment of high blood pressure, http://www.eshonline.org/esh-annual-meeting/ (2018, accessed 7 August, 2018).

14.

Sever

Dahlof

Poulter

et al.

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–2988.

15.

Abdul-Ghani

DeFronzo

Del Prato

et al.

Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived?

Diabetes Care 2017; 40: 813–820.